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Abstract
Challenges for obtaining more effective malaria vaccines depend on precise selection of
antigenic  motifs  and  understanding  the  complexity  of  Plasmodium  spp.  life  cycle.
Naturally expressed antigens are characterized for being weak immunogenic when
tested as vaccine components, thus these have to be strategically modified to render
them immunogenic.  A molecular  clue in this  pursuit  is  provided by the chemical
peptide-bond processing by peptidases, which follows a multistep pathway including
ephemeral high energy molecular complexes known as transition states. Thus, we have
proposed  non-natural  peptide-bond  isosteres  as  transition  states  mimetics,  and
therefore,  stabilizing these high-energy states with site-directed designed immuno-
mimetics  have  demonstrated  being  a  rational  approach  for  stimulating  antibody
populations  harboring  multiple  functional  capacities.  Therefore,  peptide-bond
substitutes constitute a coherent pathway towards obtaining selected immuno-active
compounds  from specific  plasmodial  molecular  objectives.  Chemical  strategies  for
synthesizing  peptido-mimetics  and  antimalarial  selected  trials  lead  us  to  assess  a
number  of  peptide-bond substitutes  for  obtaining  immuno-active  and structurally
defined  molecules.  Plasmodium  antigens  expressed  on  merozoite,  sporozoite  and
gametocyte stages have been selected as targets and subsequently modified based on
the presence of either a high-binding motif or a potential HLA-reading frame. This new
family of immuno-mimetics is and efficient neutralizing antibody inducers when tested
in in vitro and in vivo experiments, thus representing a new generation of malaria vaccine
components.
Keywords: malaria, synthetic vaccine, non-natural elements, immuno-mimetic, func-
tional antibody
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1. Introduction
Malaria is spreading from old Plasmodium colonized territories to other zones of the earth
where this lethal disease did not exist before covering about 45% of the planet. Over decades
an important number of public health trials for malaria eradication and control have been
conducted with a limited success.  Malaria is caused by Plasmodium  spp. to a susceptible
human being and is transmitted by the Anopheles female mosquito bite and is responsible of
660,000 deaths and around 219 million new cases annually (a  range of  154–289 million)
especially  in  children younger  than 5  years  of  age  and pregnant  women inhabitants  of
endemic and high transmission areas [1–3].
A number of difficulties inherent to many causes among the pathogen resistance to antima-
larials, poor coverage of public health programs and natural human host genetic restrictions
make the finding of an effective malaria vaccine be an urgent need.
Malaria vaccine development has constituted a big challenge for researchers, up-to-date about
236 vaccine candidate prototypes are being tested. Approaches based on strategies such as
immunization with irradiated sporozoites of Plasmodium spp., as well as DNA-based immu-
nogens besides recombinantly expressed antigens such as RTS,S formulated in different
vehicles and strong adjuvant systems and prototype delivery systems such as virosomes
besides to the most promising strategy constituted by synthetic peptides representing subunit
multistage immunogens formulated in human allowed adjuvants represent the main attempts
for immuno-prophylaxis [2].
Plasmodium spp. express a number of antigens, more than 100 in its different life cycle stages
and most of them have been regarded as vaccine targets such as the so-named merozoite
surface antigens 1–10 (MSP1–MSP10), erythrocyte binding antigens EBA-140 and EBA-175,
the ring-infected erythrocyte surface antigen (RESA-155), the apical membrane antigen AMA-1
among many others from the merozoite stage including a number of organelle’s proteins.
Besides the circumsporozoite surface protein (CSP), sporozoite threonine and asparagine-rich
protein (STARP), the sporozoite and liver stage antigen (SALSA), the liver stage antigen (LSA)
are some representative antigens of the sporozoite stage and the classical Pfs48/45, GSA and
Pbs25/28 from gametocytes have been regarded as the targets for transmission blocking
vaccines [4].
Natural immunity to malaria is related to hemoglobin structure, some disorders such as
thalassemia confer resistance to Plasmodium falciparum while Duffy negative RBC constitutes
the mechanisms associated to malaria resistance to Plasmodium vivax. Immune response against
a natural malaria infection is nonspecific and has a weak effect on protection. Innate immunity
mediated by NK and non-related auto antibody B-cells as well as the INF-gamma response to
infected red blood cells act as a primary line of defense against Plasmodium infection. In the
adaptative immunity step CD4+, dendritic cells, macrophages, gamma delta T cells and NKT
cells are able to detect the parasite and participate in the immune defense. Besides natural
immunity to this disease, an effective malaria vaccine can be proposed for a strong stimulation
of antibody B-cells. However, at is has been demonstrated that most Plasmodium native-derived
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sequences are proven to be poorly immunogenic and non-protection inducers against malaria.
In order to understand this problem, Patarroyo have established a strategy based on selection
of non-polymorphic regions of selected antigens and a subsequent rational mutation of those
residues belonging to red blood cells and hepatic cells binding motifs allow modified active
antigens [4], however, most clinical trials worldwide which have been performed with the
above mentioned malaria vaccine candidates have failed to achieve significant protection
levels, evidencing intrinsic difficulties for developing a potent fully protective vaccine
formulation. Perhaps pathogens including Plasmodium spp. have evolved complex mecha-
nisms to recognize, block and destroy natural-presented antigens as vaccines as well as others
related to antigen structure modulation.
Our group has introduced in this pursuit some non-natural elements to be incorporated into
synthetic antigens with the aim of governing both antigen presentation as well as specific B-
cells for functional neutralizing antibody stimulation. Some of these non-natural elements
included capture sequences for stimulating antigen degradation and others for the peptide-
bond structure modulation. Peptide-bond isosteres included reversal configuration thereof,
urea motifs and reduced amide as peptide-bond surrogates all constituting a novel immuno-
gen family herein named as immuno-mimetics.
Once strategically incorporated into selected antigens, produced peptide-bond surrogates
overcome non-desirable properties of native non-modified antigens such as cytotoxicity and
hemolytic profiles, besides prolonging these new molecules half-life and a remarkably strong
immuno-stimulating activity that can be associated to the newly introduced freedom degrees
to the 3D structure of immuno-mimetics.
Also, we have consolidated the female BALB/c animal model for malaria vaccine candidate
testing based on controlled challenging performed to immunized animals with two rodent
malaria strains, being those Plasmodium berghei ANKA and Plasmodium yoelii-17XL. Addition-
ally, passive transferring antibodies into infected animals have proven to be efficient for malaria
disease control and parasite clearance.
2. Global health statistics, economical and environment determinants
In 2015, time for fulfillment of the millennium development goals (MDGs) was getting closer
to the end, and a consequent protocol comprising 17 sustainable development goals (SDGs)
constitute the next step. In its annual report, World Health Organization (WHO) analyzed 15
years of advances of those proposed MDG and evaluated the next challenges for the coming
years.
As reported in world health statistics 2015 issued by the WHO [1], undernutrition was the
main cause of mortality in an assessed 45% of all deaths of children under 5 years of age. In
the 1990–2013 period, the estimate of underweight children in third-world countries decreased
from 28 to 17%, and a sustainable decreasing rate to 16% was expected for the end of 2015. In
spite of those proposed efforts for achievement of MDG, these numbers are not still sufficient
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to the goals. The proportion of underweight children declined globally from 25% in 1990 to
15% in 2013.
Worryingly, poverty is strongly associated with public health especially to problems related
to high transmission of infectious diseases. As observed in Figure 1A, among the main causes
of deaths among children under 5 years (in neonatal and post-neonatal ages), between 2000
and 2013 are responsibility of infectious diseases, pneumonia, malaria, HIV/AIDS, measles,
diarrhea and sepsis are the main reasons of mortality accounting 13 and 35%, respectively.
Malaria represents 7% of children mortality mainly in the post-neonatal period between 1 and
59 months of age.
Figure 1. Health statistics and world climate. (A) Causes of deaths among children under 5 years of age. (B) Top 10
countries with largest share of the global extreme poverty. (C) Main causes of child mortality due to transmissible dis-
eases. 5.9 million children under age five died in 2015, nearly 16,000 every day. (D) Climate changes and greenhouse
effect. Global average surface temperature changes under two scenarios for considering the global greenhouse gas
emissions between years 1950 and 2100. RCP for representative concentration pathway. This figure has been adapted
from information provided by WHO [1–3].
In the last year, 836 million of the world population lived on less than US$1.25 daily in
comparison with 1.9 billion in 1990. In those the so-named poor countries, 14% of the people
lived on less than US$1.25 daily in the same year, regarding the 47% in 1990. Getting closer to
an amount of US$2 daily has been difficult at higher poverty levels.
The most inhabited counties of the world such as People’s Republic of China and India have
been crucial for world reduction in poverty (indeed India remains the earth’s country having
most extreme poverty; Figure 1B) such reduction can be associated to growth of central
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economic sectors and labors. Other factors such as income transferring, remittances and
evolving new demographic profiles have had a lesser impact. However, those efforts have not
been enough since one of each seven people in poor countries live on less than US$1.25 daily.
In the sub-Saharan countries, more than 40% people are living in extreme poverty in 2015. In
the countries having middle-incomes, the 73% of the Earth’s poverty is found [3].
Figure 1B displays the top 10 countries with largest share of the global extreme poor, accord-
ingly with WHO classifications, these countries are inhabited by people living on less than US
$1.25 per day. Therefore, poverty levels show India 30%, Latin America 28%, China 8% and
dramatically 20% represents African countries (Nigeria, Democratic Republic of the Congo,
Ethiopia, United Republic of Tanzania, among others). Child mortality was 5.9 million children
under age five which died in 2015, nearly 16,000 per day, mainly caused by infectious diseases
whose distribution can be observed in Figure 1C. Main causes of child death are due to measles,
malaria, diarrhea, HIV/AIDS, meningitis/encephalitis, tetanus and sepsis and other neonatal
infections besides prematurity among other causes [1–3].
The sustainable development goals (SDGs) also contain ambitious targets for child mortality,
with SDG 3.2 seeking to end preventable deaths of newborns and children under five. Those
have included local aims for reducing the under-five mortality rates (U5MR) around to 25
deaths per 1000 live births as well as the neonatal mortality rate (NMR) to lower than 12 per
1000 live births, in comparison with a world’s U5MR rate of 43 per 1000 live births in the last
year, representing 5.9 million deaths of children under 5 years and a NMR rate of 19 per 1000
live births, representing 2.7 million deaths in the first month of life. Main causes of newborn
mortality during the last year were prematurity, birth-related complications and neonatal
sepsis, while those post-neonatal causes of death were associated to pneumonia, diarrhea,
injuries and malaria. Specifically, the so-called Target 4.2 in the document, which encourage
for assuring that most children have access to good quality development, heath assistance and
care, and basic education join to reducing child mortality while improving a better living
quality for childhood in most poor countries [3].
On the other hand, Figure 1D displays climate changes and greenhouse effect on earth for a
period between 1950 projected to the wear 2100. As described, global average surface temper-
ature change is estimated under two scenarios for turning around global greenhouse gas
emissions [1].
The global climate warming is a reality. The average data for the Earth’s surface temperature
showed a 0.85°C increasing (0.65–1.06) for the 1880–2012 period. Data show that the Earth’s
north hemisphere had the warmest period from 1983 to 2013, being the highest regarding the
last 1400 years. Without any doubt, most causes for this fact can be associated to human
activities. Mathematical and predictive algorithms for global warming-cooling allow estab-
lishing precise predictions on climate changes over long-time periods, these have included
factors such as volcanic activity and gas emissions to the atmosphere. The Intergovernmental
Panel on Climate Change’s (IPCC) for temperature changing prediction have considered a
number of factors and possibilities for future greenhouse gas emissions, which have been
termed as representative concentration pathways (RCP). This ranges from RPC 2.6 which
considers that global greenhouse gas emissions will reach a highest value between 2010 and
The Next Vaccine Generation Against Malaria: Structurally Modulated Plasmodium Antigens
http://dx.doi.org/10.5772/65251
311
2020, then it significantly decrease after 2020, to RCP 8.5, in which greenhouse gas emissions
will continue to increase during the present century. Middle-range positions consider that RCP
4.5 and 6.0 would reach the highest emission values in 2040 and 2080 in consequence [1].
World’s predictive temperature changes for 2015–2016 period regarding those recorded
between 1986 and 2005 are estimated to vary between 0.3 and 0.7°C. Similarly, increasing
temperature ranges for the 2081–2100 period regarding the recorded changes between 1986
and 2005 has been estimated to be 0.3–1.7°C (RCP 2.6) to 2.6–4.8°C (RCP 8.5) (Figure 1D). In
consequence, the Arctic region’s warming rate will increase faster than the world’s mean, and
that for the land’s rate will be higher than the mean for the ocean. Assessed RPCs led to estimate
that sea level will growth from 0.26 to 0.82 m by the final of the current age. Earth’s surface
warming and climate variations will have a deep impact on human living, health and welfare,
since obtaining drinking water and the possibility of cultivating the necessary quantities of
agricultural products and all resources required for the future world’s larger population will
be compromised.
3. Malaria: a devastating disease
Malaria is a global disease responsibly of high levels of morbidity and mortality especially in
developing countries whose inhabitant populations suffer the consequences of the disease
besides the economic impact on these populations. At the beginning of the new millennium,
a global strategy for controlling malaria by establishing a global founding for fighting three
high impact diseases, i.e., AIDS, tuberculosis and malaria have been proposed by the World
Health Organization (WHO) [5]. The 2015 world malaria report from WHO account data from
79 countries affected by this disease reflecting a slight improvement in controlling the disease
impact but the problem still remains for a solution. In 2013, diagnosis tests were expanded to
most malaria affecting countries and huge steps towards vector control were also conducted.
In 2013, the use of insecticides impregnated mosquito nets were promoted and so the amount
of populations protected against malaria were increased, thus mortality due to malaria was
reduced to 47% between the years 2000 and 2013. However, endemic areas are still far away
from reaching a total coverage for malaria control and available founding is each time
decreased for managing this important problem. An estimated 278 million people in Africa
live in households without a single insecticide mosquito net and 15 million pregnant women
have no access to a preventive treatment for malaria. In addition, other diseases affecting these
populations alter the development of related campaigns is the case of Ebola whose recent
outbreak have conducted to a decreasing in health assistance in those affected zones.
In the last five years, it is estimated that 584,000 deaths due to malaria have occurred (367,000–
755,000) of which 78% were children under 5 years of age and 90% came from Africa; today,
there are an estimated 3.2 billion people at risk of contracting the disease since are living in
areas influenced by the disease, of which 1.2 billion are at high risk (more than 1 into 1000
possibility of acquiring malaria in the year); in the Region of the Americas, it is presumed that
the risk is 120 million people in 21 countries in the region [5].
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Eradication efforts by public health preventive measures are not sufficiently effective for many
reasons, among which are the socioeconomic, demographic and technical policies, emerging
resistance to insecticides by the vector and to antimalarial drugs by the parasite [6]. In 2010,
vector resistance had been reported in 49 countries around the world of which 39 reported
resistance above two or more pyrethroid insecticides. In 2013, this report increased to 82
countries reporting insecticide resistance [3], therefore, to develop an effective vaccine against
the disease becomes an urgent need.
By 1967, major efforts were made to find an effective vaccine against human malaria, in one of
the most important related studies of the time, 59% protection was achieved after an intrave-
nous challenge of a malaria murine model after being vaccinated with 75,000 live attenuated
irradiated sporozoites [7].
Currently among vaccine candidates that are in more advanced clinical trials are the RTS,S and
PfSPZ which incorporates the use of non-replicative attenuated sporozoites through controlled
radiation [8], which has obtained a dose dependent protection in humans being necessary the
application of 1.35 × 105 attenuated sporozoites in five doses [9]. It should be noted that the
duration of protective antibodies has not been fully established, thus obtaining a vaccine is not
a reality.
As can be observed in Figure 2, global malaria spreading accounts for more than 80 countries
that are affected by malaria infection (purple background in the map). Besides, insecticide
susceptibility status for malaria vectors (Anopheles female mosquitoes) demonstrates a
resistance increasing to most insecticides concomitant with areas of high transmission of
malaria.
Figure 2. Areas of risk of malaria transmission and ongoing malaria vaccine candidate trials.
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4. Plasmodium spp. life cycle
A deep knowledge and understanding of the Plasmodium parasite life cycle would be a key
step towards antigen discovery, and it will establish the molecular basis for a proper immu-
nogen designing to be further tested as a vaccine candidate. The Plasmodium spp. belong to the
phylum Apicomplexa being the causative agent of malaria, whose clinical and pathological
manifestations are associated with asexual erythrocytic stage of the parasite [10].
There are five species of Plasmodium causing human malaria, the most lethal disease is caused
by P. falciparum and followed by P. vivax, and less prevalent are Plasmodium malariae and
Plasmodium ovale [11] in 2011 Plasmodium knowlesi was included in this list. In Colombia for the
year 2014, 356 clinical cases of uncomplicated malaria were reported, 20,074 cases of malaria
by P. vivax, 19,789 by P. falciparum, 17 cases by P. malariae and 561 cases of mixed malaria
according to data presented by the National Institute of Health (INS) in its weekly report
SIVIGILA [12].
Plasmodium parasites have a complex life cycle involving interactions of invertebrates (vector)
and vertebrates (mammalian host), besides presenting various stages in intracellular and
extracellular environments (Figure 3) [13].
Figure 3. Plasmodium life cycle. Main pre-erythrocyte, blood and sexual stages are denoted.
In the human host, sporozoites are inoculated by the bite of female Anopheles spp. mosquitoes,
then invade hepatocytes in a time between 5 and 30 min; within hepatocytes each sporozoite
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develops a schizont which release between 10,000 ± 30,000 merozoites to blood stream during
a period of 2 ± 10 days depending on the parasite specie [14], in the case of P. vivax and P. ovale
also it produces a different stage in the liver called hypnozoite, which is a silent form respon-
sible for the subsequent relapses [11]. During the travel from the skin to the liver, the parasites
cross the capillary epithelium in the dermis and enter to blood circulation, cross the hepatic
sinusoids epithelium to enter the parenchyma, and this process as the hepatocyte infection are
given by activity of the myosin-actin engine located in the plasma membrane of the parasite
and its rhoptries, dense granules and micronemes [15].
The invasion of erythrocytes occurs after several steps with multiple interactions between
receptor membrane proteins of host cells and parasite protein ligands expressed in its surface
as well as in rhoptries and micronemes [16]. The parasite grows and divides in about 72–48 h
according to the specie to the schizont stage which contains more than 30 merozoite particles,
which are released with the subsequent invasion and replication in healthy erythrocytes [17].
Acquired immune response induced by malaria parasites is complex and varies depending on
the level of endemicity, epidemiology, genetic, age of the host, parasitic stage and parasite
species. Repeated infections and continued exposure are required to achieve clinical immunity
with symptom reduction and reduced number of parasites in an infected individual or
inhibition of parasite replication [18].
5. The murine model in the search for vaccine candidates against malaria
The mouse model has been widely used in the study on malaria, and it has been regarded as
a practical model for experimental studies since its genetical features regarding human beings
such as homology and similarity at the protein structure level, physiology and life cycle besides
of owning a malaria transmission vector (Anopheles stephensi) that can be maintained under
defined laboratory [19].
Due to this, there are several Plasmodium strains that infect rodent models by malaria (P. berghei,
P. yoelii, P. chabaudi, P. vincker), and their experimental behavior can be extrapolated due to the
fulfillment of a standard life cycle under controlled conditions. The two most commonly
employed strains in malaria vaccine discovery are the P. yoelii and P. berghei, which have high
similarity with the clinical symptoms and pathology developed by P. falciparum in relation to
those stages of cerebral malaria, placental malaria, severe malaria and organ damage as liver,
kidney and lung [20]. The P. berghei infection model has allowed demonstrating the role of
interferon in response to parasite replication in the liver, and this participation was then
demonstrated in P. falciparum [20].
The rodent malaria infection by P. yoelii has allowed to demonstrate that humans immu-
nized with the PfCS protein from the parasite sporozoite stage, induced antibodies that cross-
react with P. yoelii, as well as mice immunized with PyCSP stimulated antibodies that cross-
react with P. falciparum; therefore, this model evidenced its usefulness as a predictive tool for
immune response against certain malarial antigens since there are a 70% of genome similari-
ty between P. yoelii and P. falciparum [14]. This similarity associate at least 3300 orthologous
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genes of P. yoelii with 5268 genes of P. falciparum [21]. Although the erythrocytic cycle of P.
berghei and P. yoelii takes place more rapidly (24 and 18 h, respectively) compared to those
developed in P. falciparum (36–48 h) and P. vivax (48 h), differences in tropism for invasion of
reticulocytes in the case of P. yoelii and P. berghei are not presented in P. falciparum and the
genetic similarity between these Plasmodium is quite important, and so the rate of increase in
parasitemia levels is similar during the first 3–4 days after inoculation in vitro as well as the
parasite growth [22]. Also, in vivo conditions and clinical symptoms associated to the disease
are presented in terms of fever, malaise, splenomegaly and breathlessness related with red
blood cells rupture which differ of symptoms present in infections with other strains such as
P. chabaudi where in contrast the infection is associated with hypothermia [23]. The production
and regulation in the cytokines expression are no exception to the similarity between the mouse
model and a malaria human infection since P. yoelii and P. berghei replicate many events that
can be correlated between both of the infection types [24, 25].
In studies at the level of liver infection cycle were found that about 654 (92%) of proteins in P.
yoelii correlated with orthologous sequences present in P. falciparum and 66% of the genes in
the P. yoelii transcriptome have orthologues in P. falciparum [26]. Also in this stage of infection,
it has been possible to obtain in vivo images in models of infection with P. berghei in mice, these
have shown details of hepatocyte invasion by Plasmodium which were not yet known in
humans, as well as the fact that sporozoites can recognize heparan-sulfate proteoglycans
besides that P. yoelii infection models have been conducted to tests the oxidative stress in the
liver induced by infected erythrocytic forms [27].
Bearing in mind, the possibilities offered by murine infection models, we have conducted an
important amount of experiments in order to test a variety of chemically modified antigens as
potential vaccine components.
In spite of impressive economic and political efforts conducted by WHO and other non-
government organizations for malaria eradication and control, based on insecticide treatment
of bed-nets (mainly DTT), use of new formulations of artemisinin and other antimalarials for
treatment of infected patients and teaching about an appropriate water and environment care
to inhabitants of malaria high-transmission areas, among other strategies, malaria still remains
as one of the most important health problems for developing countries. Contrary to those
expectations, most of these strategies have failed for malaria control, mainly due to novel and
powerful biological evolution of antimalarials-resistance mechanisms developed by Plasmo‐
dium parasites, joint to the continuous mosquito adaptation and colonization of new environ-
ments and territories, climate changing and global warming due to non-controlled gas
emissions to the atmosphere. Therefore, hopes for controlling this lethal disease are based on
developing more efficient preventive strategies and highly potent malaria vaccines.
Up-to-date, about 236 including chemoprophylaxis and malaria vaccines clinical trials are
being conducted worldwide, most of them have been completed showing a limited success (as
shown in Figure 2). Most conducted studies have been focused on vaccine candidates aimed
to block three different potential targets, being the transmission-blocking approach the first
(gametocyte-derived proteins such as Pf25 and Pf125); secondly, those candidates directed
against Plasmodium liver-malaria stages (considering proteins such as Circumsporozoite
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surface protein (CSP), liver stage antigen (LSA), sporozoite and liver stage antigen (SALSA),
Thrombospondin-related anonymous protein (TRAP) and others) and vaccine candidates
directed against malaria blood stages (classical merozoite protein targets are Merozoite surface
proteins 1-10 (MSP-1-10), apical membrane antigen-1 (AMA-1), ring-infected erythrocyte
surface antigen (RESA-155), serine repeat antigen (SERA), Erythrocyte binding antigen 175
(EBA-175) among others).
As recently mentioned by Birkett in 2015, the European Medicines Agency announced a
positive opinion for the malaria vaccine candidate most advanced in development, RTS,S/
AS01, which provides modest protection against clinical malaria in all conducted trials, but in
spite of its poor efficacy later in 2016, this product was recommended by WHO for large-scale
trials in moderate to high malaria transmission areas [28]. As observed in Figure 2, 113 trials
of pharmaceutical products among antimalarials and vaccine formulations are being conduct-
ed in Africa in high-transmission malaria regions by immunizing mainly with modified or
attenuated sporozoite NF54 strain malarial parasites or other products such as the so-named
biological PfSPZ vaccine all of them formulated on strong adjuvant systems such as AS01 as
can be observed in the web site ClinicalTrials.gov, a service of the U.S. National Institutes of
Health [29].
Due to the moderate success conducted in the last three decades of researching for finding
highly potent vaccines for preventing malaria, the field is open for new ideas regarding the
discovery of strategies for developing structurally modulated molecular probes which
address the Plasmodium complex molecular mechanisms involved in parasite detection, facing
the challenge of demonstrating protective efficacy profiles and parasite clearance capacity, so
those would enter the pathway of being regarded as components of novel vaccine formula-
tions.
6. Current status of P. vivax vaccine progress
Morbidity to malaria outside of the sub-Saharan Africa still remains meaningful causing more
than 50% of malaria cases, especially in the Americas and Pacific-Asia where poverty and
public health systems are associate to multiple problems. The complex P. vivax biology and its
ability to differentiate into latent forms called hypnozoites which appear longtime later to
produce erythrocyte infective forms, prompt occurrence of macro and micro gametes previous
to clinical manifestations are seeming, and thus a short evolution cycle into the mosquito makes
useless using standard tools to control P. vivax. Simultaneously to decreasing in global
incidence, some dramatic changes in pathogen infective species have been reported by P. vivax
being currently the prevalent Plasmodium spp. in those mentioned world regions.
For multiple reasons, the epidemiologic spreading of malaria due to P. vivax is being regarded
as careless. However, turning on attention to malaria caused by P. vivax has to be a priority
when thinking in a vaccine against malaria. Most approaches for a P. vivax malaria vaccine
candidate have considered orthologous sequences among the most predominant Plasmodium
species as being P. falciparum and P. vivax especially antigens of both pre-erythrocyte and
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erythrocyte stages. Among a number of vaccine candidates, the VMP001/AS01 targets the CSP
antigen of P. vivax. This has been assessed in controlled human malaria infection (CHMI)
studies but proven to be unsuccessful with poor protection capacity. Another candidate, which
is a recombinantly expressed on appropriate virus, targets the TRAP antigen and currently is
currently in study and another prototype vaccine candidate is based on using the strategy of
attenuated sporozoites.
On the other hand, the most focused P. vivax erythrocyte-stage antigen is the Duffy binding
protein (DBP), which is considered crucial for red blood cell (RBC) invasion; however, the DBP
non-conserved character establishes an important hindrance. Importantly, time of protection
against malaria would be more relevant for a P. vivax vaccine regarding a P. falciparum vaccine
due to P. vivax disease incidence is not focused in given populations as it is for P. falciparum.
Hepatic P. vivax-stages also contribute to reinforce this problem complexity [30, 31].
Therefore, developing potent P. vivax vaccines would depend on several key aspects among
establishing a continuous P. vivax—culture in enriched reticulocyte media or specific growth
factors aimed to reproducing parasite infections, also appropriate animal models for vaccine
candidate testing and most importantly the right selection of multi antigen formulations in
human adjuvants and delivery systems, thus peptido-mimetics would play a role in this
pursuit.
7. The meaning of being non-visible to α/β-TCR of T lymphocytes
It is well known the fact that the T-cell receptor sees antigen on the surface of cells associated
with an MHC class I or II molecule. Therefore, activating humoral and cell-mediated immune
responses requires factors such as cytokines and costimulatory molecules expressed by Th
cells. A fine and specific regulation of Th has to be highly regulated in order to avoid any self-
reactivity would conduct to auto-immune disorders. In order to ensure the Th-cells activation
and regulation, these have to recognize a given antigen that is being presented in the MHC
class-II context which is located on an antigen presenting cell (APC) surface. As it is known,
these professional presenting cells among macrophages, dendritic cells and B lymphocytes
harbor two relevant features: (1) surface expression of class-II (MHC-II) molecules, and (2)
recruitment of costimulatory molecules as signals for activation of Th-cells.
Antigen-presenting cells first internalize antigen, and then display a part of that antigen on
their membrane bound to a MHC-II molecule. The TH cell recognizes and interacts with the
antigen–MHC-II molecule complex on the membrane of the antigen-presenting cell. Immune
system is prepared for antigen presentation by stabilizing MHC-II molecules in the endoplas-
mic reticulum bound to an endogen invariant Ii chain which is later cleaved to a small peptide
called class II-associated invariant chain peptide (CLIP) which remains bound to the MHC-II
molecule to be then replaced by a given antigen-peptide assisted by a chaperone molecule
named HLA-DM in endosomal compartments. Therefore, the antigen-MHC-II bimolecular
complex will travel to the APC membrane surface to be presented to T-cell receptors (TCR) of
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T-lymphocytes to establish and stabilize in consequence specific ternary complexes able to
trigger CD4+TH cell proliferation and so an immune response.
As mentioned one of the main functions of CLIP is to prevent the binding of self-peptide
fragments prior to the MHC II localization within the endosome-lysosome, a consensus
primary structure of CLIP is 87PVSKMRMATPLLMQA101, which is able to a proper interaction
with a HLA-II molecule by anchoring-specific residues to the so-named pockets 1, 3, 4 and 9
of the MHC-II molecule in such a way that its entire structure will remain buried into the HLA-
II molecule. The CLIP-HLA-II (CLIP: HLA-DR3) molecular complex is shown in Figure 4. As
observed, the endogenous peptide is hidden into the presenting HLA-II molecule, and the
possibility of being recognized by any TCR is completely abolished, and so an auto-reactive
immune response will not take place, thus if a given pathogen can develop immune response
evasion mechanisms based on its ligands structure features, it would be desirable to its
convenience to resemble the most relevant structure characteristics of CLIP to avoid be
recognized by TCRs [32].
Figure 4. An endogen peptide-MHC-II bimolecular complex. The endogenous invariable Ii-chain cleaved CLIP prod-
uct (87PVSKMRMATPLLMQA101) complexed to a HLA-DR3 allele. Coordinates of the CLIP-HLA-DR3 complex from
the protein data bank (PDB) coded 1A6A corresponded to the structure determined by X-ray diffraction at a 2.75 Å
resolution, was downloaded and molecular modeled with the visual molecular dynamics (VMD1.7ή) software of the
University of Illinois at Urbana-Champaign. Color code representation for HLAII α-chain in purple, β-chain in cyan,
HA peptide is represented in amino acid id code [32].
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8. How to become recognized by a TCR-T lymphocyte
Influenza hemagglutinin (HA) or hemagglutinin is a glycoprotein found on the surface of
influenza viruses. Its role is to bind the influenza viruses to their target cells through sialic acid,
specifically to red blood cells and upper respiratory tract cells [33, 34]. Once the pH has been
decreased, a second role of HA is to join the viral cover to formed endosomes. HA is an integral
membrane glycoprotein expressed as homo-trimers which seem a barrel-like structure having
around 13.5 nm in length. HA is confirmed by three monomers built into a alpha-helical core
displaying spherical tips containing those sialic acid-binding motifs. HA is synthesized as
monomeric units as precursor forms which are glycosylated and processed on protein
maturation, to produce two shorter proteins called HA1 and HA2. The HA monomers are long
helical chains attached to the cell membrane by HA2 and capped by HA1. Thus, HA has been
responsible for stimulation of neutralizing antibodies which are proven to avoid influenza
virus infection to its target cells, thus constituting an important molecular tool for infection
control using mechanisms associated to ternary complex stabilization of HA-HLA-II α/β-TCR
(CD4+) with specific HLA-DR4 alleles such as DRA*0101 and DRB1*0401 [34].
Figure 5. Reactive and T-lymphocyte proliferation upon a stabilized ternary HA-hemagglutinin-HLAII-TCR com-
plex. Coordinates of the human T-cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocom-
patibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401) were downloaded from the protein data
bank (PDB) whose code 1J8H corresponded to structure obtained by X-ray diffraction at a 2.40 Å resolution, and then
was molecular modeled with the visual molecular dynamics (VMD1.7ή) software of the University of Illinois at Ur-
bana-Champaign. Color code representation for HLAII α-chain in purple, β-chain in cyan, HA peptide is represented
in amino acid id code, TCR α-chain in yellow and β-chain in green [34].
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Figure 5 recreates the 3D structure of the HA-hemagglutinin-HLAII-TCR ternary complex. As
observed, the HA306–318 peptide backbone whose amino acid sequence is PKYVKQNTL-
KLAT anchor-specific residues into the HLA-II 1, 3, 4 and 9 pockets and clearly expose some
residues in positions 5, 8 and 7 to be recognized by α/β-TCR chains and so stabilizing the
molecular complex. However, the HA peptide binds promiscuously and can be presented by
most of the frequently occurring DR alleles. Therefore, CD4+ T-lymphocyte proliferation would
lead a subsequent neutralizing antibody production able to block the influenza virus infection,
being this molecular interaction an effective mechanism effectively used for the immune
response. As this a number of similar immuno-reactive complexes have been described [35–40].
9. New modified vaccine components containing non-natural elements
considering chiral and topochemical constraints
Current prototype vaccines against malaria are failed to the goal of protecting any individual
living in high risk malaria transmission areas even the most promising such as RTS,S which
have less than 30% effectivity. As discussed above, the complex life cycle of Plasmodium
parasites besides human genetic restrictions and immune mechanisms associated with
protection makes obtaining an effective malaria vaccine a challenge. Therefore, obtaining new
immunogens as vaccines and other molecular systems having potential application in malaria
therapy would have to be with precisely selecting relevant antigens which would be submitted
for steps of redesigning, production, formulation and in vitro tested before assayed in animal
models; thus, after proven to be effective have to cross the border line for human clinical trials.
The aim of our research is to produce back-bone modified immunogenic antigens which
included non-natural elements such as chiral and peptide-bond substitutions directed to
modulate the antigen 3D structure and stimulation of neutralizing antibodies. Our approach
is based on low-polymorphic sequences of Plasmodium which are then modified into immu-
nological relevant motifs as well as strategically including lysosomal substrates to stimulate
processing and presentation steps on vaccinated individuals. Therefore, we have analyzed and
produced representative modified immunogens based on a number of native sequences
belonging to different stages of Plasmodium which upon vaccination of animal models have
proven to be effective against malaria infection and parasite clearance [41–43].
One of our first approaches for antigen peptide backbone modification consisted in introducing
topochemical elements into the selected antigen primary structure, which consisted in two key
features, first the amino acids chirality and second the peptide backbone space orientation. As
represented in Figure 6A, the N-terminus low polymorphic region of the PfMSP142-61 native
sequence (GYSLFQKEKMVLNEGTSGTA) was the base for evaluating the above described
considerations. Thus, chirality impact on immunogenic properties was tested by introducing
local and global l- and d-amino acid substitutions, and the peptide backbone orientation
influence was assessed by reversing the primary structure but upholding its native composi-
tion. Therefore, a set of peptido-mimetic analogues were designed and synthesized and
subsequently tested. As observed, the experimental group consisted in the PfMSP142-61 native
The Next Vaccine Generation Against Malaria: Structurally Modulated Plasmodium Antigens
http://dx.doi.org/10.5772/65251
321
sequence, entirely made of l-amino acids; its chiral D-analogue which preserved the sequence
and was built with d-amino acids (represented in lowercase letters); another so-named Retro
analogue sequence, which was constructed with d-amino acids and reversing the sequence
orientation and an analogue called Retro-inverso, which was synthesized with l-amino acids
and reversing the peptide sequence orientation. Also punctual or partially D-substitutions
were include in the experimental group. CD profiles for the four molecules reflected interesting
spectrophotometric properties, thus when comparing the native L-sequence (black line) with
its D-enantiomer (red line), their CD profiles behave as specular images of one another as
displayed in Figure 6B. Similarly, CD profile for the L-native sequence compared with that
of the Retro-inverso analogue (green line), behave as mirror images of each other bearing in
mind that both were made with only l-amino acids, but having opposite peptide backbone
orientation.
Figure 6. Chiral and topochemical peptido-mimetic designing. (A) Molecular peptido-mimetic design based on the
N-terminus PfMSP142-61 peptide. The native sequence is represented in capital letters for l-amino acids, D-enantiomer
represented by lowercase letters purple highlighted, Retro-sequence is constituted by d-amino acids in lowercase let-
ters blue highlighted and the so-named Retro-inverso peptidomimetic is confirmed by l-amino acids green highlight-
ed. (B) Circular dichroism secondary structure patterns for PfMSP142-61 peptido-mimetics. Used color code was black
line for the native sequence, purple for its D-enantiomer, blue line for the Retro-analogue and green line for the Retro-
inverso peptido-mimetic. Competition ELISA was used for the PfMSP142-61 peptide mapping with monoclonal antibod-
ies coded Ig-αψ-437(52V-L53) and Ig-αψ-439(51M-V52) as shown in (C) and (D), respectively. IC50 μM values represent
the average of data obtained in triplicate.
CD patterns for the D-enantiomer and the Retro-inverso analogue had a close relationship
regarding the all-L native sequence. On the other hand, CD profiles for the all-D-enantiomer
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(red line) and the Retro-analogue (blue line) behaved as specular images of each other, keeping
in mind that these molecules are made of only d-amino acids, having the second a reversed
backbone regarding the first. Interestingly, CD patterns of both, the L-native sequence and
Retro-analogue resemble each other but are opposite to the CD profile of the D-enantiomer.
Therefore, a partial conclusion emerged from these findings, independently of the amino acid
composition; backbone orientation seemed to play a key role for the 3D structure properties
of the antigen molecule.
In order to test the unique recognition of an antibody stimulated by a reduced amide peptido-
mimetic in which the oxygen atom of the carbonyl group (–R–CO–NH–R′–) of a relevant
peptide-bond was replaced with two hydrogen atoms to lead an analogue being the reduced
form of it and herein named reduced amide peptido-mimetic ψ(–R–CH2–NH–R′–). Thus, two
monoclonal immunoglobulins (mAb) were produced, one directed to PfMSP142-61 modified
between the -52V-L53- and another directed to the -51M-V52- amino acid pairs, respectively, which
herein are named as Igα-ψ-VL52-53 and Igα-ψ-MV51-52. Both mAbs possess inhibitory capacities
in both in vitro and in vivo malaria infections by P. falciparum as well as P. yoelii and P. berghei
as elsewhere published [42]. Also our experiments allowed to a fine mapping of the MSP-1 N-
terminus portion using monoclonal and polyclonal antibodies induced by reduced amide
peptido-mimetics of the PfMSP142-61 peptide and so we identified the antigen epitope whose
amino acid sequence is 51MVLNEGTSGTA61 as elsewhere reported [44].
Therefore, a whole set of PfMSP142-61 modified analogues were used in competition assays for
their ability to bind these mAbs. As observed in Figure 6C and D, the non-modified native
sequence (all-L) bound at a 10 μg/mL while their inducer modified peptido-mimetics did it at
a 1 μg/mL concentration. The reduced amide modification between 49E-K50 residues was an
excellent competitor for binding to the Igα-ψ-MV51-52. Interestingly, the All-D-enantiomer and
Retro-inverso form of the sequence behaved as strong competitors for the Igα-ψ-VL52-53
binding, both of them are built with d-amino acids. In a similar way, most partially made D-
substitutions were strong binders to both tested antibodies. Thus, both chirality and back-bone
orientation become critical properties for antigen-antibody recognition, considering that
natural features have to be resembled in artificially-modified immunogens, as well as pre-
serving the molecule structure topology but most relevant it is an appropriate side-chain space
orientation, which will be crucial for binding and functional effects.
In another set of experiments conducted based on the C-terminus low polymorphic portion
the MSP1 antigen, the PfMSP11282-1301 peptide whose primary structure EVLYLKPLAG-
VYRSLKKQLE was the basis for protection capacity assays against malaria in Aotus monkeys
immunized with reduced amide peptido-mimetics and partially made D-mutations. Animals
were treated in agreement with Colombian and environmental regulations, and those indi-
viduals that developed malaria infection after being experimentally challenged with controlled
doses of P. falciparum were subjected to medication to ensure their health conditions.
As observed in Figure 7, a few number of animals vaccinated have controlled the Plasmodium
parasitemia levels, especially two out of ten vaccinated with the reduced amide ψ-7P-L8
peptido-mimetic and four out of eight with a partial D-substitution in K6 of the PfMSP-11282-1301
sequence.
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Figure 7. Protection capacity of PfMSP-1/1282-1301 peptido-mimetics. (A) Aotus monkeys immunized with the
PfMSP-11282-1301 native sequence. (B) Animal group immunized with the ψ-9475 (7P-L8) reduced amide peptido-mimetic
analogue. (C) Animals immunized with the partially substituted D-L8 analogue. (D) Group of animals immunized
with the partially substituted D-K6 analogue. (E) Aotus monkeys immunized with saline solution as the placebo con-
trol group.
On the contrary, animals of the placebo-control and those vaccinated with the native sequence
became faster infected and did not control the Plasmodium parasitemia. Therefore, the evidence
supported the relevance of chiral-space occupancy as well as topochemical modifications as
being important elements to be considered for malaria vaccine designing.
In order to be consisting with our proposed molecular models, we decided to focus our
attention in another relevant Plasmodium antigen, the so-named PfMSP-2 surface antigen.
Specifically, we have designed and synthesized some reduced amide peptido-mimetics based
on the N-terminus PfMSP221-40 peptide whose amino acid sequence is KNESKYSNTFIN-
NAYNMSIR. Thus, two peptido-mimetic analogues coded ψ-128 and ψ-130 which were
modified between the 30F-I31 and 31I-N32 amino acid pairs, respectively, were obtained and
characterized. Our experiments for a fine PfMSP221-40 sequence mapping with monoclonal
antibodies directed to both modified motifs have revealed a functional epitope whose exact
location was 25KYSNTFIN32 as previously published [45].
As observed in Figure 8, the reactivity patterns of both antibodies by western blot analyses
lead to identified native PfMSP2 protein fragments stained at 30.54, 34.21 and 37.90 kDa on a
P. falciparum FCB-2 membrane protein lysate. Faster polypeptide fragments of PfMSP2 on the
SDS-PAGE, could be associated to this antigen cleavage during blood-stage parasite matura-
tion to mature schizonts, previously to merozoite releasing (Figure 8A).
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Figure 8. Reactivity and functional properties of PfMSP221-40 peptido-mimetics. (A) Plasmodium falciparum FCB-2
membrane protein lysed resolved on a 7.5–15% SDS-PAGE gradient system. (B) Recombinant MSP2-(His)6 protein
treated with the Ig-αψ-128 (30F-I31) monoclonal antibody. (C) Recombinant MSP2-(His)6 protein treated with the Ig-
αψ-130 (31I-N32) monoclonal antibody. (D) Surface membrane proteins from blood stages of P. berghei treated with the
Ig-αψ-128 and Ig-αψ-130 monoclonal antibodies. (E) Surface membrane proteins from blood stages of P. yoelii treated
with the Ig-αψ-128 and Ig-αψ-130 monoclonal antibodies. (F) BALB/c mice infected with lethal doses of rodent malaria
treated by passive transference of Ig-αψ-128 and Ig-αψ-130 monoclonal antibodies.
In order to verify the antibody reactivity, an Escherichia coli recombinantly MSP2 expressed
fragment which contained part of the PfMSP2 N-terminus sequence was employed. Hence, the
Ig-αψ-128 antibody detected lysate produced bands at 30.06 and 36.50 kDa and the Ig-αψ-130
antibody recognize bands at 34.71 and 35.50 kDa, all polypeptide bands contained the MSP2
recombinantly expressed fragment as compared with the control raw, as shown in Figure 8B,
C respectively.
Similarly, a lysate composed by membrane proteins from blood stages of P. berghei and P. yoelii
were analyzed for these mAbs recognition. Therefore both Ig-αψ-128 and Ig-αψ-130 antibodies
detected bands at 50.11 and 63.09 kDa mobilities for P. berghei ANKA and 44.46 and 50.11 kDa
for the P. yoelii 17XL strain, respectively, as observed in Figure 8D and E. Besides, functional
in vivo activity of these antibodies was tested by passive transferring experiments of both into
P. berghei and P. yoelii infected BALB/c mice groups. Most animals survived to the lethal
challenging with Plasmodium strains and efficiently have controlled parasitemia levels due to
the antibody therapeutic activity as it was published and observed in Figure 8F [45]. This set
of experiments revealed the importance of performing peptide-backbone strategic modifica-
tions by introducing non-natural elements into the immunogen primary structure, but its
amino acid sequence identity has to be preserved to avoid any non-specific or non-desirable
cross-reactive effects.
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To obtain a complete landscape of this novel scenario, further scopes of the strategy of obtaining
next generations of malaria vaccine candidates based on introducing non-natural elements
into immunogens, trials performed in selected antigens of other Plasmodium stages, such as
those called pre-erythrocytic as well as sexual forms on macro and micro-gamete particles have
to be conducted. Hence, the circumsporozoite surface protein (CSP) expressed on pre-
erythrocyte forms offers a classical interesting target for vaccine candidate development.
As reported before, a class-I restricted PbCSP252-260 epitope was identified in the CSP primary
structure of Plasmodium berghei, a rodent malaria specie [46–49]. Thus, in order to test our
hypothesis, we conducted experiments by introducing reduced amide peptide-bond isosteres
in a systematic fashion and their subsequent evaluation regarding antibody stimulation and
their reactivity was performed. This epitope whose amino acid sequence is SYIPSAEKI was
the basis for the molecular designing. Thus, a set of peptido-mimetic analogues were synthe-
sized and characterized. As shown in Figure 9B and C, antibodies induced by the PbCSP252-260
native sequence have some reactivity for both sporozoite and gametocytes as analyzed by
indirect immunofluorescence assays (IFA) experiments while a stronger reactivity of the
modified 257A-E258 amino acid pair of PbCSP257-258 peptido-mimetic-induced antibodies, become
evident regarding both sporozoites and gametocytes as observed in Figure 9E and F. Anti-
bodies of pre-immune sera did not show any reactivity as seen in Figure 9A and D.
Figure 9. Exploring immunological properties of the restricted class‐I PbCSP252‐260 epitope by indirect immunofluor‐
escence assays (IFA). (A) Pre-immune serum of mouse 2. (B) Plasmodium falciparum sporozoites detected by antibodies
induced by the PbCSP252-260 native peptide post-third boost (mouse 2), image captured at 2 μm. (C) Detection of Plasmo‐
dium falciparum (NF54 strain) gametocytes by antibodies induced by the PfCSP252-260 native sequence post-third boost
(mouse 2), and image recorded at 2 μm. (D) Reactivity of pre-immune serum of mouse 23. (E) Detection of Plasmodium
falciparum sporozoites by antibodies to the PbCSP (A–E) peptido-mimetic obtained post-third boost (mouse 23), image
recorded at 1 μm. (F) Detection of Plasmodium falciparum (NF54 strain) gametocytes by antibodies directed to the
PbCSP (A–E) peptido-mimetic (mouse 23), and image captured at 2 μm.
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The proposed hypothesis has been confirmed by challenging it in different molecular scenar-
ios, all based on analysis of different antigens derived from different Plasmodium species and
stages and proved in in vivo and in vitro assays. Thus, an emerging conclusion states the
importance of a careful and strategic molecular designing of potential malaria vaccine
candidates which consider the antigen global structure modulation but preserving their
specific fingerprint represented by their amino acid sequence.
Aimed to understand a possible structure-immunological activity relationship, a subsequent
set of nuclear magnetic resonance NMR and molecular dynamic in silico experiments lead us
to compare in all cases, both the native antigen, as well as their modified derivatives regarding
their 3D structure properties. Thus, generated data are presented in Figure 10, in which either
native antigen backbone conformation is overlapped with that of its functional representative
peptido-mimetics or polypeptide conformations of homologue proteins in two Plasmodium
species are compared.
Figure 10. Structure-immunological activity relationship. Overlapped backbone of native and modified peptido-mim-
etic analogues were organized as follow. (A) Accessible solvent surface of the PfMSP142-61 native sequence in white and
ψ-437 in red ribbons and ψ-439 in blue ribbons. (B) Accessible solvent surface of the PfMSP11282-1301 native sequence,
ψ-9473 in blue ribbons and ψ-9475 in red ribbons. (C) Accessible solvent surface of the PfMSP221-40 native sequence,
ψ-128 in purple ribbons and ψ-130 in ochre ribbons. (D) Accessible solvent surfaces in white for PfCSP and blue for
PbCSP. The 308SYIPSAEKI316 class-I restricted epitope is highlighted.
As observed in Figure 10A, overlapped 3D conformations of the N-terminus PfMSP142-61
peptide whose solvent accessible surface depicted in white, and two of its peptido-mimetics
those coded as ψ-437 (52V-L53) and ψ-439 (51M-V52) represented by red and green ribbons,
revealed deep structure differences between them. A highly compact α-helix structure present
in the native sequence became flexible in its two peptido-mimetic analogues due to a single
peptide bond modification, in which the oxygen atom of the –CO–NH– amide function of a
specific peptide-bond, was replaced with two hydrogen atoms so leading –CH2–NH– surro-
gates.
Similarly, backbone of the low polymorphic C-terminus of the same PfMSP1 antigen specifi-
cally the PfMSP-11282-1301 peptide fragment (solvent accessible surface in white) was overlapped
with its two derive ψ-9473 (6K-P7) and ψ-9475 (7P-L8) peptido-mimetics (red and blue ribbons)
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[50]. As in the first analyzed case, a highly compact α-helix structure present in the native
sequence became flexible in its two peptido-mimetic analogues due to single peptide bond
modifications which surely have introduced new freedom degrees to the molecule, as seen in
Figure 10B.
On the other hand, backbone structural analyses for the PfMSP221-40 regarding its two ψ-128
(30F-I31) and ψ-130 (31I-N32) reduced amide peptido-mimetics, revealed a close-related behavior
regarding the couple of the above discussed examples for a different Plasmodium protein, the
PfMSP1. Figure 10C, displays the β-stranded conformation of the native sequence (solvent
accessible surface depicted in white) regarding the more flexible conformations of both of its
peptido-mimetics (represented by purple and ochre ribbons).
An interesting observation become evident when backbone of two homologue proteins are
overlapped regarding a class-I epitope region, as it was the case of the PfCSP and PbCSP, as
shown in Figure 10D; consisted in that those overlapped polypeptide conformations, suggest
an intermediate molecular state among them, which could be represented by a peptido-
mimetic structure probe. Thus, the peptido-mimetic coded PbCSP252-260 which represents a
peptide-bond surrogate located between the 257A-E258 amino acid pair, thus this strategic
peptide-bond replacement could be responsibly of the stimulated cross-reactive antibodies.
Further experiments in this pursuit will explore hypothesis on in vivo protection against
malaria regarding CSP peptido-mimetics and will be conducted in order to assess the func-
tional inhibitory activity of peptido-mimetics and their antibodies on malaria-infected mice
through Anopheles albimanus mosquito bites.
The family of the herein presented structural modified compounds constitute molecular tools
to be considered for new generations of functional protective vaccines against malaria, as such,
future vaccine candidates could be based on this knowledge and outstanding findings.
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